Kyle R.

Kyle R. is an accomplished finance and healthcare professional currently serving as the Chief Financial Officer at Lexeo Therapeutics since December 2024. Prior experience includes leadership roles such as Chief Business Officer at Zentalis Pharmaceuticals, and Managing Director at Eventide Asset Management, where Kyle led the healthcare investment team and co-managed a high-performing mutual fund. Additionally, Kyle held positions as Managing Partner at Pappas Capital, Vice President of Pharmaceutical Equity Research at Cowen and Company, and an Equity Research Analyst at T. Rowe Price. Early in the career, Kyle contributed to research at Dana-Farber Cancer Institute and Harvard Medical School, focusing on treatments for neuromuscular disorders. Educational qualifications include a PhD in Pharmaceutical and Biomedical Sciences and a Doctor of Pharmacy from the Medical University of South Carolina, an MBA from The Citadel, and a BS in Biology from Denison University. Kyle is also certified with Series 7, 63, 86, and 87 licenses.